Aldosterone Synthase Inhibitors (ASIs)

The Next Frontier in Hypertension: Aldosterone Synthase Inhibitors (ASIs)

The landscape for treating resistant hypertension and Chronic Kidney Disease (CKD) is shifting. While Mineralocorticoid Receptor Antagonists (MRAs) have long been the standard, a new class of therapeutics is stepping into the spotlight: Aldosterone Synthase Inhibitors (ASIs).

With the FDA's anticipated 2026 decisions on Baxdrostat and Lorundrostat, the "Patent Thicket" around Aldosterone Synthase Inhibitors (ASIs) is becoming a critical study for pharmaceutical IP strategists.

The clinical promise of ASIs is clear, but their market impact will be governed by supply chain resilience.

hashtag#Pharma hashtag#Hypertension hashtag#CKD hashtag#DrugDiscovery hashtag#Cardiology hashtag#ClinicalTrials hashtag#ASIs hashtag#Innovation hashtag#PharmaceuticalSourcing hashtag#SupplyChain hashtag#API hashtag#ChemicalManufacturing hashtag#CDMO hashtag#PharmaLogistics hashtag#DrugDevelopment hashtag#IntellectualProperty hashtag#PatentLaw hashtag#PharmaIP hashtag#Baxdrostat hashtag#Lorundrostat hashtag#FTO hashtag#DrugExclusivity hashtag#Peptide hashtag#Semaglutide